Zymeworks Inc
NYSE:ZYME
Zymeworks Inc
NYSE:ZYME
Price:
9.15 USD
1.67%
Market Closed
Updated:
May 16, 2024
Zymeworks Inc
Income from Continuing Operations
|
Zymeworks Inc
Income from Continuing Operations Peer Comparison
Comparables:
TH
RPTX
FUSN
AUPH
EDT
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Zymeworks Inc
NYSE:ZYME
|
Income from Continuing Operations
-$118.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Income from Continuing Operations
-$18m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-7%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Income from Continuing Operations
-$93.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Income from Continuing Operations
-$94.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Income from Continuing Operations
-$62.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-25%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Income from Continuing Operations
-CA$15.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-3%
|
See Also
What is Zymeworks Inc's Income from Continuing Operations?
Income from Continuing Operations
-118.7m
USD
-118.7m
USD
Based on the financial report for Dec 31, 2023, Zymeworks Inc's Income from Continuing Operations amounts to -118.7m USD.
What is Zymeworks Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-27%
-27%
The average annual Income from Continuing Operations growth rates for Zymeworks Inc have been 13% over the past three years , -27% over the past five years .
You don't have any saved screeners yet
